10-Q
Quarterly Report
ACTINIUM PHARMACEUTICALS, INC.
ATNM
NYSE
CIK: 1388320
File #: 001-36374
Balance Sheet
27 line items · 2 periods
XBRL
| Item | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|
Current Assets: | ||
Cash and cash equivalents | 84,057,000 | 76,677,000 |
Prepaid expenses and other current assets | 1,316,000 | 1,586,000 |
Total Current Assets | 85,373,000 | 78,263,000 |
Property and equipment, net of accumulated depreciation of $760 and $694 | 496,000 | 550,000 |
Restricted cash – long term | 316,000 | 313,000 |
Operating leases right-of-use assets | 2,140,000 | 2,289,000 |
Finance leases right-of-use assets | 27,000 | 30,000 |
Total Assets | 88,352,000 | 81,445,000 |
Current Liabilities: | ||
Accounts payable and accrued expenses | 7,513,000 | 7,953,000 |
Operating leases current liability | 540,000 | 530,000 |
Finance leases current liability | 11,000 | 11,000 |
Total Current Liabilities | 8,064,000 | 8,494,000 |
Long-term license revenue deferred | 35,000,000 | 35,000,000 |
Long-term operating lease obligations | 1,414,000 | 1,553,000 |
Long-term finance lease obligations | 17,000 | 19,000 |
Total Liabilities | 44,495,000 | 45,066,000 |
Stockholders’ Equity: | ||
Common stock, $0.001 par value; 1,000,000,000 shares authorized; 29,396,411 and 27,634,213 shares issued and outstanding, respectively | 29,000 | 28,000 |
Additional paid-in capital | 390,081,000 | 373,934,000 |
Accumulated deficit | (346,253,000) | (337,583,000) |
Total Stockholders’ Equity | 43,857,000 | 36,379,000 |
Common Stock | 29,000 | 28,000 |
Additional Paid-In Capital | 390,081,000 | 373,934,000 |
Accumulated Deficit | (346,253,000) | (337,583,000) |
Total Liabilities and Stockholders’ Equity | 88,352,000 | 81,445,000 |